Physician

Catherine Anne O'Brien, M.D.

According to 2025 Medicare claims, Catherine O'Brien, M.D. (NPI: 1417994047) practices hematology/oncology in the Portland-Vancouver-Hillsboro, OR-WA market, with the plurality of this provider's patient population coming from Yamhill, OR. This provider's primary affiliated billing organization is OREGON ONCOLOGY SPECIALISTS, LLP (NPI: 1649206780; TIN: 93-1273254) and primary practice location at 97128-6258.

O'Brien's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 379 traditional Medicare patients, billed 131,497 HCPCS/CPT codes, and received $2,828,769 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,668 prescription claims across 299 beneficiaries totaling $4,804,333 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 42 claims. Open Payments data shows 12 records totaling $301. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $826,030 to $2,828,769. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,248,509 to $4,804,333. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,675 to $1,028.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	306	89,398	$826,030
2016	331	133,141	$1,180,228
2017	332	109,157	$1,201,090
2018	338	82,001	$1,240,808
2019	362	148,180	$2,344,705
2020	397	117,322	$2,326,868
2021	413	92,206	$1,654,152
2022	387	104,478	$2,158,526
2023	369	107,823	$2,434,344
2024	379	131,497	$2,828,769

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	238	1,955	$1,248,509
2016	258	2,411	$2,656,132
2017	279	2,231	$2,345,233
2018	266	1,803	$2,879,911
2019	260	1,600	$3,313,119
2020	263	1,728	$4,761,069
2021	309	1,848	$5,108,341
2022	330	1,733	$4,658,675
2023	289	1,547	$4,629,191
2024	299	1,668	$4,804,333

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	34	$4,008
2016	N/R	25	$1,058
2017	N/R	49	$1,961
2018	N/R	51	$2,528
2019	N/R	37	$3,161
2020	N/R	150	$9,948
2021	N/R	131	$9,060
2022	N/R	108	$4,329
2023	N/R	68	$8,117
2024	N/R	42	$1,113

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	56	56	$126
96413	Administration of chemotherapy into vein, 1 hour or less	53	326	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	99	202	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	280	563	$67
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	59	136	$48

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	68	1,904	$873,048
Calquence	Acalabrutinib Maleate	44	1,320	$833,984
Jakafi	Ruxolitinib Phosphate	36	1,057	$617,743
Imbruvica	Ibrutinib	21	588	$344,336
Ibrance	Palbociclib	21	588	$337,324

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$680
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$301	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Catherine Anne O'Brien, M.D.?

Tedicare shows public-source Medicare data for Catherine Anne O'Brien, M.D. (NPI 1417994047), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Catherine Anne O'Brien, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Catherine Anne O'Brien, M.D.?

Catherine Anne O'Brien, M.D. is linked to OREGON ONCOLOGY SPECIALISTS, LLP (billing NPI 1649206780) in the available physician profile data.

Does Catherine Anne O'Brien, M.D. have Open Payments data?

Catherine Anne O'Brien, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.